These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 33576769)

  • 1. JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study.
    Le Voyer T; Gitiaux C; Authier FJ; Bodemer C; Melki I; Quartier P; Aeschlimann F; Isapof A; Herbeuval JP; Bondet V; Charuel JL; Frémond ML; Duffy D; Rodero MP; Bader-Meunier B
    Rheumatology (Oxford); 2021 Dec; 60(12):5801-5808. PubMed ID: 33576769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JAK inhibitors in refractory juvenile rheumatic diseases: Efficacy, tolerance and type-I interferon profiling, a single center retrospective study.
    Solignac M; Cabrera N; Fouillet-Desjonqueres M; Duquesne A; Laurent A; Foray AP; Viel S; Zekre F; Belot A
    J Autoimmun; 2024 Jul; 147():103248. PubMed ID: 38797048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with Janus kinase inhibitors in juvenile dermatomyositis: A review of the literature.
    Sener S; Cam V; Ozen S; Batu ED
    Semin Arthritis Rheum; 2024 Jun; 66():152426. PubMed ID: 38442462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic changes from type I interferons and JAK inhibitors: clues to drivers of juvenile dermatomyositis.
    Covert LT; Prinz JA; Swain-Lenz D; Dvergsten J; Truskey GA
    Rheumatology (Oxford); 2024 Sep; 63(SI2):SI240-SI248. PubMed ID: 38317053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world single centre use of JAK inhibitors across the rheumatoid arthritis pathway.
    Fitton J; Melville AR; Emery P; Nam JL; Buch MH
    Rheumatology (Oxford); 2021 Sep; 60(9):4048-4054. PubMed ID: 33331938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JAK inhibitors in the treatment of adult patients with juvenile idiopathic arthritis: a retrospective monocentric experience.
    Chighizola CB; Pellico MR; Pandolfi M; Marelli L; Cornalba M; Pontikaki I; Costi S; Gattinara M; Marino A; Miserocchi E; Caporali R
    Clin Exp Rheumatol; 2024 May; 42(5):974-982. PubMed ID: 38530666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of janus kinase inhibitors in relapsing giant cell arteritis in real-world clinical practice and review of the literature.
    Loricera J; Tofade T; Prieto-Peña D; Romero-Yuste S; de Miguel E; Riveros-Frutos A; Ferraz-Amaro I; Labrador E; Maiz O; Becerra E; Narváez J; Galíndez-Agirregoikoa E; González-Fernández I; Urruticoechea-Arana A; Ramos-Calvo Á; López-Gutiérrez F; Castañeda S; Unizony S; Blanco R
    Arthritis Res Ther; 2024 Jun; 26(1):116. PubMed ID: 38840219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Higher infection risk for JAK inhibitors tofacitinib and baricitinib compared to subcutaneous biological DMARDs.
    Opdam MAA; Broeder ND; van den Bemt BJF; Mulder K; van de Wiel KM; van Ballegooijen H; van Crevel R; den Broeder AA
    Clin Rheumatol; 2024 Jun; 43(6):2133-2138. PubMed ID: 38703283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world comparative study of drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis.
    Saito K; Yoshida S; Ebina H; Miyata M; Suzuki E; Kanno T; Sumichika Y; Matsumoto H; Temmoku J; Fujita Y; Matsuoka N; Asano T; Sato S; Migita K
    PLoS One; 2024; 19(7):e0306714. PubMed ID: 38990897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prior herpes zoster occurrence and high-dose corticosteroids increase herpes zoster risk in rheumatoid arthritis patients receiving janus kinase inhibitors in a retrospective and observational study.
    Chen PK; Chang SH; Chen YM; Chen HH; Huang PH; Huang CC; Yeo KJ; Lan JL; Chen DY
    Clin Rheumatol; 2024 Aug; 43(8):2503-2511. PubMed ID: 38954278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Janus kinase inhibitors ruxolitinib and baricitinib impair glycoprotein-VI mediated platelet function.
    Parra-Izquierdo I; Melrose AR; Pang J; Lakshmanan HHS; Reitsma SE; Vavilapalli SH; Larson MK; Shatzel JJ; McCarty OJT; Aslan JE
    Platelets; 2022 Apr; 33(3):404-415. PubMed ID: 34097573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study.
    Ebina K; Hirano T; Maeda Y; Yamamoto W; Hashimoto M; Murata K; Onishi A; Jinno S; Hara R; Son Y; Amuro H; Takeuchi T; Yoshikawa A; Katayama M; Yamamoto K; Okita Y; Hirao M; Etani Y; Kumanogoh A; Okada S; Nakata K
    Sci Rep; 2022 Jan; 12(1):134. PubMed ID: 34997059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful management with Janus kinase inhibitor tofacitinib in refractory juvenile dermatomyositis: a pilot study and literature review.
    Yu Z; Wang L; Quan M; Zhang T; Song H
    Rheumatology (Oxford); 2021 Apr; 60(4):1700-1707. PubMed ID: 33024992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term follow-up of Janus-kinase inhibitor and novel active disease biomarker in juvenile dermatomyositis.
    Huang B; Wang X; Niu Y; Ding Y; Wang X; Tan Q; Li Y; Liu Y; Chi Y; Wang Y; Zhou Z; Li J
    Rheumatology (Oxford); 2023 Mar; 62(3):1227-1237. PubMed ID: 35904570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Updates on efficacy and safety janus kinase inhibitors in juvenile dermatomyositis.
    Kim H
    Expert Rev Clin Immunol; 2024 Jun; 20(6):589-602. PubMed ID: 38299575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis.
    Kim H; Dill S; O'Brien M; Vian L; Li X; Manukyan M; Jain M; Adeojo LW; George J; Perez M; Grom AA; Sutter M; Feldman BM; Yao L; Millwood M; Brundidge A; Pichard DC; Cowen EW; Shi Y; Lu S; Tsai WL; Gadina M; Rider LG; Colbert RA
    Ann Rheum Dis; 2021 Mar; 80(3):406-408. PubMed ID: 32843325
    [No Abstract]   [Full Text] [Related]  

  • 17. Oral Janus Kinase Inhibitors in Pediatric Atopic Dermatitis.
    Navarrete-Rodríguez EM; Larenas-Linnemann D; Vidaurri de la Cruz H; Luna-Pech JA; Guevara Sanginés E
    Curr Allergy Asthma Rep; 2024 Sep; 24(9):485-496. PubMed ID: 39105881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis.
    Chen CX; Wang JJ; Li H; Yuan LT; Gale RP; Liang Y
    Leukemia; 2021 Sep; 35(9):2616-2620. PubMed ID: 33990684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world utilisation and switching between Janus kinase inhibitors in Australian patients with rheumatoid arthritis in the OPAL dataset.
    Ciciriello S; Littlejohn GO; Treuer T; Gibson KA; Haladyj E; Youssef P; Bird P; O'Sullivan C; Smith T; Deakin CT
    Clin Exp Rheumatol; 2024 Sep; 42(9):1763-1772. PubMed ID: 38757292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Janus kinase inhibitors for atopic dermatitis: a promising treatment modality.
    Cartron AM; Nguyen TH; Roh YS; Kwatra MM; Kwatra SG
    Clin Exp Dermatol; 2021 Jul; 46(5):820-824. PubMed ID: 33484582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.